Last updated 6 days ago

AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

1200 patients around the world
Available in Argentina, Brazil, Puerto Rico, United States
Novo Nordisk A/S
13Research sites
1200Patients around the world

This study is for people with

Diabetes
Diabetes mellitus type 2

Requirements for the patient

From 18 Years
All Gender

Medical requirements

Male or female (sex assigned at birth, inclusive of all gender identities).
Age 18 years or above at the time of signing the informed consent.
Diagnosed with type 2 diabetes (T2D) above or equal to 180 days before screening.
On stable daily dose(s) of metformin, sodium-glucose transport 2 (SGLT2) inhibitor, or both (at effective or maximum tolerated dose as judged by the investigator) prior to screening.
Glycated haemoglobin (HbA1c) as determined by central laboratory at screening.
Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening.
Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening.
Planned coronary, carotid or peripheral artery revascularisation.
Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria before screening. However, insulin treatment for gestational diabetes is allowed as well as short term insulin treatment for a maximum of 14 consecutive days.
Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.
Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening.
Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.

Sites

Organización Médica de Investigación (OMI)
Uruguay 725 PB , Buenos Aires, CP: 1015
Instituto de Investigaciones Clínicas Mar del Plata
Instituto de Investigaciones Clínicas Mar del Plata
Av. Colón 3456, Mar del Plata, Buenos Aires
Centro de Investigaciones Clínicas Baigorria
Centro de Investigaciones Clínicas Baigorria
San Jorge 204, S2152BOF Granadero Baigorria, Santa Fe, Argentina
Instituto de Investigaciones Clínicas San Nicolás
Instituto de Investigaciones Clínicas San Nicolás
Pellegrini 346, San Nicolás
Mains Bleues
F. Dentesano 627, S2300 Rafaela, Santa Fe, Argentina
Centro de Diagnóstico y Rehabilitación - CEDIR
SAN MARTIN 3169 – Santa Fe, Santa Fe. CP 3000
Cicemo - CABA
Eduardo Acevedo 42, C1405BUB Cdad. Autónoma de Buenos Aires, Argentina
CPQuali Pesquisa Clínica
Avenida Angélica, 916 Conjunto 506 - São Paulo 01228-000
Hospital e Maternidade Celso Pierro
Campinas, 13590-900
Núcleo de Pesquisa Clínica do Rio Grande do Sul - NPCRS
Rua Mostardeiro 5/310, Porto Alegre, Rio Grande do Sul
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy